article thumbnail

Building Korro Bio: A CEO’s Perspective on Innovation and Risk Management

LifeSciVC

Founding Vision: Harnessing RNA Editing for Transformative Medicine Korro Bio’s story began in 2018, co-founded by a remarkable group: Jean-François Formela, M.D. Academic specializing in RNA editing). The ability of modifying RNA enabled us to sidestep many of the potential risks associated with permanent DNA editing.

RNA 67
article thumbnail

Protein Science & Structural Biology

Sygnature Discovery

We’ve successfully tackled targets for: Unprecedented membrane proteins Intrinsically disordered proteins Refolding from inclusion bodies Large protein complexes Labelled proteins for NMR studies RNA structures by crystallography Across our capabilities Protein Expression & Purification Vast diversity of proteins produced.

Science 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Future of Drug Discovery: Tackling the Undruggable with New Biotechnologies

DrugBank

Indirectly Targeting "Undruggable" Proteins Small molecules can also target "undruggable" proteins indirectly by modulating the production of these proteins. This can be achieved by influencing chromatin regulation or targeting transcription factors and RNA molecules that control protein expression.

article thumbnail

Accelerating Riboswitch Engineering for the Development of Human Performance Biosensors - A Preview of Strateos’ Presentation at SynBioBeta 2021

The Strateos Blog: Drug Discovery

Learn how Strateos’ automated synthetic biology modules supported rapid, iterative screening of RNA sequences in modular pbuE expression system and E. coli extract-based cell-free protein expression assays.

article thumbnail

The Role of Oncology Biomarkers in Personalizing Hematology Treatment Plans

Conversations in Drug Development Trends

Molecular Biomarkers : Encompass various molecules, such as RNA and metabolites, to reflect the physiological state of the cells and their disease pathways. Proteomics Proteomics involves studying the entire set of proteins expressed in a cell or tissue.

article thumbnail

Biopharma Money on the Move: December 2 – 8

The Pharma Data

Laying down a new track for RNA processing, Remix launched with $81 million in financing. Funds will be used to support development of the REMaster technology platform and advance the company’s pipeline of RNA processing targeted therapeutics as well. “As Pear Therapeutics.

RNA 52
article thumbnail

Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study

The Pharma Data

The CureVac-GSK COVID-19 collaboration announced in February 2021 extends the existing strategic mRNA technology partnership both companies started in July 2020, which focuses on the development of new products based on CureVac’s second-generation RNA-technology for different targets in the field of infectious diseases.